References
- A controlled trial of a human papillomavirus type 16 vaccine. Koutsky LA, Ault KA, Wheeler CMet al. N Engl J Med. 2002 Nov 21;347(21):1645-51.
- Cancer Vaccines: Between the Idea and the Reality. Finn OJ. Nat Rev Immunol. 2003 Aug;3(8):630-41. Reviewed by Ryan P. Smith, MD
- Breast cancer vaccine tests encouraging
- A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Sato Y, Maeda Y, Shomura H et al. Br J Cancer. 2004 Apr 5;90(7):1334-42.
- Cancer vaccine shows promise in phase I human trial
- Cancer Vaccine Triggers Immune System to Recognize Melanoma. ASCO 1998.
- Cancer vaccine induces integrated immune response, novel monitoring shows
- Breast cancer vaccine generates immune response in cancer patients
- Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.Su Z, Dannull J, Heiser A er al. Cancer Res. 2003 May 1;63(9):2127-33.
- Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. Berd D, Sato T, Maguire HC Jr et al. J Clin Oncol. 2004 Feb 1;22(3):403-15. Epub 2003 Dec 22.
- Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. Kaufman HL, Wang W, Manola J et al. J Clin Oncol. 2004 Jun 1;22(11):2122-32.
- Merck, Biomira cancer vaccine stumbles. /resources/article.cfm?c=3&s=8&ss=23&id=9801&month=06&year=2003
- Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. Sondak VK, Liu PY, Tuthill RJ et al. J Clin Oncol. 2002 Apr 15;20(8):2058-66.
- Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Jocham D, Richter A, Hoffmann L et al. Lancet. 2004 Feb 21;363(9409):594-9.
|